CATEGORY : Clinical Diagnostics

Life Science Market Reports

Our life science market intelligence products have been recognized by market insiders and outsiders alike for their accuracy, in-depth analysis, and unique insights.

Market Reports

Select 2019 Trends and Discussions

  Los Angeles, CA January 3, 2019 – The end the last decade deepened my personal belief that the personalized medicine revolution will be driven by tools and diagnostics, rather

QIAGEN to Become Thermo?

In mid-November, speculation began that ThermoFisher was in talks with QIAGEN surrounding a potential acquisition. A hypothetical tie-up could help Thermo bolster its reach into clinical diagnostic tests and nucleic

Dx FTW

Los Angeles, CA November 26, 2019 – At DeciBio, we believe that the precision medicine revolution will be driven by improvements in life science research tools and diagnostics technologies! A

Pain Points, Unmet Needs, and Disruption in Precision Medicine – Part 1

DeciBio’s mission is to provide market intelligence and strategic insights that drive disruption and innovation in the precision medicine and life science industry. To this end, my colleague, Colin Enderlein,

An Updated Look at TMB: What Has Changed and What to Expect

Since we last reported on the rise of tumor mutational burden (TMB) in immuno-oncology (I/O) a year ago, there have been numerous material developments of this biomarker in the I/O

Pulse Survey: Adoption and Utilization of Next Generation Cancer Biomarkers

The way cancer is diagnosed, treated, and monitored is changing more rapidly than ever. In 2019, we expect there to be catalysts that fundamentally change cancer companion diagnostic biomarker testing (i.e.,

Guardant Health stock soars after IPO, Lexent Bio joins the serial monitoring gold rush and a UK research team develops a novel cfDNA assay

Want to keep up with the latest liquid biopsy market research developments? Take our 6 minute survey and sign up for our weekly newsletter. DeciBio Liquid Biopsy Weekly Digest September 27, 2018

New CRISPR Companies Heat Up as Skepticism Grows

Novel ways of harnessing CRISPR disrupt diagnostics, therapeutics, and food systems While much hype has been built around CRISPR-Cas9 and its ability to revolutionize treatment of genetic disorders and disease,

Exploring Collaboration Networks within Liquid Biopsy Research

Background Network graphs have always amazed me. This concept has been around for a long time now and has been leveraged by scientists to explain a wide variety of phenomena